FDA investigating risk of secondary cancers after CAR-T therapy to treat cancer

FDA Investigation: The U.S. Food and Drug Administration is investigating the risk of secondary cancers associated with CAR-T cancer therapies.

Reports of T-cell Malignancies: There have been 19 reports of T-cell malignancies, including lymphoma, in patients who received CAR-T treatments.

Nature of CAR-T Therapy: CAR-T therapy involves genetically modifying a patient's T cells to target and attack cancer cells.

Concerns Despite Benefits: While CAR-T therapies are effective for treating certain cancers like multiple myeloma, lymphomas, and leukemias, there are serious concerns about the risk of developing T-cell malignancies.

Recommendation for Lifelong Monitoring: The FDA recommends that patients treated with CAR-T therapies be monitored for life for the development of new malignancies.